Previous 10 | Next 10 |
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, wil...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris. At the special meeting o...
Sanofi makes a second purchase just six weeks after its $2 billion deal for Translate Bio. Potential deal in the works, Columbia Property Trust comes to fruition. Macquarie Infrastructure Partners completes the acquisition of Cincinnati Bell. For further details see: Mer...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharma...
All participants received initial dose Preliminary results anticipated in Q1 2022 Compelling pre-clinical data show potential for subcutaneous administration Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel f...
Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals DUBLIN, Ireland and TREVOSE, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) --...
M&A and SPAC activity are back on track. Two rumored deals materialize at significant premiums. Five active deals completed successfully. For further details see: Merger Arbitrage Mondays - Landmark Infrastructure Partners Acquired By Its General Partner At A Signifi...
DUBLIN, Ireland and TREVOSE, Pa., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”) today announced that the leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended th...
Urges stockholders to vote “FOR” all transaction-related proposals at the Xeris special meeting to be held virtually on September 14, 2021 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Sh...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...